Literature DB >> 23100348

Screening of male patients for Trichomonas vaginalis with transcription-mediated amplification in a community with a high prevalence of sexually transmitted infection.

Kimber L Munson1, Maureen Napierala, Erik Munson, Ronald F Schell, Timothy Kramme, Cheryl Miller, Jeanne E Hryciuk.   

Abstract

Trichomonas vaginalis infection in males has been largely uncharacterized. Past reports indicated increased susceptibility to other sexually transmitted infection (STI) agents such as human immunodeficiency virus and Neisseria gonorrhoeae with concurrent T. vaginalis infection. This warrants a more thorough review of male T. vaginalis incidence. A retrospective 3-year investigation of transcription-mediated amplification (TMA)-based urethral swab and first-void urine screening for T. vaginalis within a regional health care system was performed to address T. vaginalis prevalence in males. Of 622 total samples tested, 6.6% were positive for T. vaginalis. Delineation of all specimens by ZIP code of patient residence revealed 11 predominant ZIP codes with respect to testing volume and detection rates. Within these 11 ZIP codes, representing 78.3% of total testing volume, urine was the preferred specimen source compared to urethral swabs. Seven of these 11 ZIP codes contained majority African American populations. The aggregate T. vaginalis detection rate trended higher than that of the remaining four ZIP codes, which were comprised primarily of Caucasian populations (8.9% versus 5.0%, respectively; P = 0.15). The average age of a T. vaginalis-infected male (39.9 years) was significantly greater than those for Chlamydia trachomatis or N. gonorrhoeae (27.6 and 25.9 years, respectively; P < 0.001). Given the significant rate of T. vaginalis detection, with age distribution analogous to that reported in females, TMA-based detection of T. vaginalis can be a routine constituent within a comprehensive STI screening panel for males in high-prevalence STI communities.

Entities:  

Mesh:

Year:  2012        PMID: 23100348      PMCID: PMC3536231          DOI: 10.1128/JCM.02526-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Comparison between the Gen-Probe transcription-mediated amplification Trichomonas vaginalis research assay and real-time PCR for Trichomonas vaginalis detection using a Roche LightCycler instrument with female self-obtained vaginal swab samples and male urine samples.

Authors:  Andrew Hardick; Justin Hardick; Billie Jo Wood; Charlotte Gaydos
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

2.  The prevalence of trichomoniasis in young adults in the United States.

Authors:  William C Miller; Heidi Swygard; Marcia M Hobbs; Carol A Ford; Mark S Handcock; Martina Morris; John L Schmitz; Myron S Cohen; Kathleen Mullan Harris; J Richard Udry
Journal:  Sex Transm Dis       Date:  2005-10       Impact factor: 2.830

3.  Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial.

Authors:  Jane R Schwebke; Marcia M Hobbs; Stephanie N Taylor; Arlene C Sena; Michael G Catania; Barbara S Weinbaum; Ann D Johnson; Damon K Getman; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

4.  Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians.

Authors:  Jill S Huppert; Elizabeth Hesse; Grace Kim; Michael Kim; Patricia Agreda; Nicole Quinn; Charlotte Gaydos
Journal:  Sex Transm Infect       Date:  2010-06-30       Impact factor: 3.519

5.  Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised.

Authors:  Julius Schachter; Joan M Chow; Holly Howard; Gail Bolan; Jeanne Moncada
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

6.  Three-year history of transcription-mediated amplification-based Trichomonas vaginalis analyte-specific reagent testing in a subacute care patient population.

Authors:  Maureen Napierala; Erik Munson; Kimber L Munson; Timothy Kramme; Cheryl Miller; Jason Burtch; Robin Olson; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

7.  Improved detection by DNA amplification of Trichomonas vaginalis in males.

Authors:  Jane R Schwebke; Lisa F Lawing
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

8.  Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial.

Authors:  Siobhan Sutcliffe; John F Alderete; Cathee Till; Phyllis J Goodman; Ann W Hsing; Jonathan M Zenilman; Angelo M De Marzo; Elizabeth A Platz
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

9.  Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.

Authors:  Jennifer R Stark; Gregory Judson; John F Alderete; Vasanthakrishna Mundodi; Ashwini S Kucknoor; Edward L Giovannucci; Elizabeth A Platz; Siobhan Sutcliffe; Katja Fall; Tobias Kurth; Jing Ma; Meir J Stampfer; Lorelei A Mucci
Journal:  J Natl Cancer Inst       Date:  2009-09-09       Impact factor: 13.506

10.  Impact of Trichomonas vaginalis transcription-mediated amplification-based analyte-specific-reagent testing in a metropolitan setting of high sexually transmitted disease prevalence.

Authors:  Erik Munson; Maureen Napierala; Robin Olson; Tina Endes; Timothy Block; Jeanne E Hryciuk; Ronald F Schell
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

View more
  7 in total

1.  Trichomoniasis in older individuals: a preliminary report from Iran.

Authors:  Zohreh Momeni; Javid Sadraei; Bahram Kazemi; Abdolhossein Dalimi
Journal:  J Parasit Dis       Date:  2016-01-12

2.  Expansion of Comprehensive Screening of Male Sexually Transmitted Infection Clinic Attendees with Mycoplasma genitalium and Trichomonas vaginalis Molecular Assessment: a Retrospective Analysis.

Authors:  Erik Munson; David Wenten; Sheila Jhansale; Mary Kay Schuknecht; Nicki Pantuso; Joshua Gerritts; Aaron Steward; Kimber L Munson; Maureen Napierala; Deb Hamer
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

3.  Retrospective assessment of transcription-mediated amplification-based screening for Trichomonas vaginalis in male sexually transmitted infection clinic patients.

Authors:  Erik Munson; David Wenten; Paula Phipps; Roger Gremminger; Mary Kay Schuknecht; Maureen Napierala; Deb Hamer; Robin Olson; Ronald F Schell; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

4.  Identification, characterization, and synthesis of peptide epitopes and a recombinant six-epitope protein for Trichomonas vaginalis serodiagnosis.

Authors:  J F Alderete; Calvin J Neace
Journal:  Immunotargets Ther       Date:  2013-08-12

5.  Epidemiology of Trichomoniasis in South Korea and Increasing Trend in Incidence, Health Insurance Review and Assessment 2009-2014.

Authors:  So-Young Joo; Youn-Kyoung Goo; Jae-Sook Ryu; Sang-Eun Lee; Won Kee Lee; Dong-Il Chung; Yeonchul Hong
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

6.  Codetection of Trichomonas vaginalis and Candida albicans by PCR in urine samples in a low-risk population attended in a clinic first level in central Veracruz, Mexico.

Authors:  A López-Monteon; F S Gómez-Figueroa; G Ramos-Poceros; D Guzmán-Gómez; A Ramos-Ligonio
Journal:  Biomed Res Int       Date:  2013-08-29       Impact factor: 3.411

7.  Neglected parasitic infections in the United States: trichomoniasis.

Authors:  W Evan Secor; Elissa Meites; Michelle C Starr; Kimberly A Workowski
Journal:  Am J Trop Med Hyg       Date:  2014-05       Impact factor: 2.345

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.